Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Patients with S-phase ≥5% and especially ≥10% have extremely poor ASCT outcomes (median PFS 13 and 3.5 months, respectively), identifying a functionally high-risk group that may derive little or no benefit from standard ASCT.”
Title: Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes
Authors: Tamer Hellou, Daniel G. Packard, Suheil Albert Atallah-Yunes, Ahauve M. Orusa, Shinichiro Suzuki, Shaji K. Kumar, Angela Dispenzieri, Saurabh Zanwar, Dragan Jevremovic, Horatiu Olteanu, Pedro Horna, Gregory Otteson, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Prashant Kapoor, Nelson Leung, Joselle Cook, Nadine Abdallah, Moritz Binder, Eli Muchtar, Rahma Warsame, Taxiarchis V. Kourelis, Ronald S. Go, Yi Lin, S. Vincent Rajkumar, Wilson I. Gonsalves, Morie A. Gertz
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
